All News

Found 124 articles

• Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022

  4/25/2023

  Gracell Biotechnologies Inc. announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission on April 25, 2023.

• Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences - March 22, 2023

  3/22/2023

  Gracell Biotechnologies Inc. announced that the management team will participate in two upcoming investor conferences.

• Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update

  3/13/2023

  Gracell Biotechnologies Inc. today reported fourth quarter and full year 2022 unaudited financial results for the period ended December 31, 2022, and provided corporate updates.

• Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference

  2/28/2023

  Gracell Biotechnologies Inc. today announced that the management team will participate in the Oppenheimer 33rd Annual Healthcare Conference from March 13th to 15th.  

• Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023

  2/27/2023

  Gracell Biotechnologies Inc. today announced that it plans to release unaudited financial results for the fourth quarter ended December 31, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, March 13, 2023.

• Gracell Biotechnologies to Participate in Two Upcoming February 2023 Investor Conferences

  2/14/2023

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the management team will participate in two upcoming investor conferences.

• Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

  2/13/2023

  Gracell Biotechnologies Inc. today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has cleared Gracell's Investigational New Drug (IND) application for GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM).

• Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

  2/3/2023

  Gracell Biotechnologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application and the Company can proceed to initiate a Phase 1b/2 clinical trial in the U.S. of GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM).

• Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

  12/10/2022

  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced the clinical data from its ongoing Phase 1, investigator-initiated trial in China evaluating FasTCAR-enabled GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma patients.

• Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences - November 23, 2022

  11/23/2022

  Gracell Biotechnologies Inc. today announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.

• Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award

  11/16/2022

  Gracell Biotechnologies Inc today announced that its FasTCAR Autologous CAR-T Platform was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards.

• Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update

  11/14/2022

  Gracell Biotechnologies Inc. today reported third quarter unaudited financial results for the period ended September 30, 2022, and provided corporate updates.

• Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition

  11/3/2022

  Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL) today announced the first clinical data of its ongoing Phase 1, investigator-initiated study in China evaluating FasTCAR-enabled GC012F in newly diagnosed, transplant-eligible, high-risk multiple myeloma (NDMM) patients.

• Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022

  10/31/2022

  Gracell Biotechnologies Inc. today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 14, 2022.

• Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

  10/24/2022

  Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two investor conferences in November 2022.

• Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

  10/17/2022

  Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL) today announced that the first patient has been dosed in the Phase 2 portion of its registrational Phase 1/2 clinical trial evaluating GC007g for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) being conducted in China.

• Gracell Biotechnologies to Participate in Three Upcoming September 2022 Investor Conferences

  9/14/2022

  Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at three investor conferences in September 2022 as follows.

• Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences in September 2022

  8/29/2022

  Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at four investor conferences in September 2022.

• 

  U.S. and China Reportedly Near Deal to Avoid NASDAQ Delisting

  8/26/2022

  The United States and China are reportedly close to an agreement that would allow the PCAOB to audit companies listed on the U.S. stock exchange, per the Wall Street Journal.

• Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update

  8/15/2022

  Gracell Biotechnologies Inc. today reported second quarter unaudited financial results for the period ended June 30, 2022, and provided corporate updates.